Spectral AI Inc (MDAI)
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
$1.57+0.64%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
QuarterlyIQ Insights · MDAI
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Achieve initial commercial sales of the DeepView System in the U.S. and internationally by the end of 2026 following FDA clearance and UKCA authorization updates.
Stated as a priority in 2 recent disclosures. The company received FDA clearance in 2026-Q2 enabling commercial sales by year end 2026. Revenue declined from $5.1M in 2025-Q2 to $3.5M in 2026-Q2 reflecting transition from development to commercial phase. The company reiterates 2026 revenue guidance of approximately $18.5M, excluding material sales from DeepView System. The trajectory shows progress toward commercial launch but revenue impact is not yet material.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“CEO: 'The receipt of De Novo clearance from the FDA for our DeepView System has cleared us to achieve our first commercial sales by year end 2026.'”
Maintain revenue guidance of about $18.5 million for fiscal year 2026, primarily from development contracts and excluding commercial sales.
Stated as a priority in 3 disclosures including 2025-FY and 2026-Q1 and Q2. Revenue declined slightly from $3.99M in 2026-Q1 to $3.52M in 2026-Q2. The company reiterates 2026 full-year revenue guidance of approximately $18.5M, primarily from development contracts and excluding commercial sales. The trajectory is stable with guidance maintained but revenue has declined quarter-over-quarter.
“The Company is reiterating revenue of approximately $18.5 million for the year ending December 31, 2026.”
“The Company is forecasting revenue of approximately $18.5 million for the year ending December 31, 2026.”
“The Company reiterates its revenue guidance of approximately $21.5 million for FY 2025.”
Enhance commercial capabilities by hiring a Chief Commercial Officer to support the rollout of the DeepView System.
Newly stated in 2026-Q3 period. The company appointed a Chief Commercial Officer in July 2026 to strengthen commercial leadership ahead of planned DeepView System sales. There is no direct financial impact yet visible in the reported results. This is a preparatory talent investment aligned with the commercial launch priority.
Over the trailing year it converted 1.42x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
18 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.